Kura Oncology (NASDAQ:KURA) Reaches New 12-Month Low – Time to Sell?

Kura Oncology, Inc. (NASDAQ:KURA)’s stock price reached a new 52-week low on Tuesday . The company traded as low as $6.34 and last traded at $6.38, with a volume of 434096 shares. The stock had previously closed at $6.60.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. BTIG Research lowered Kura Oncology from a “buy” rating to a “neutral” rating in a research report on Thursday, February 6th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Kura Oncology in a report on Thursday, February 27th. Cantor Fitzgerald raised Kura Oncology to a “strong-buy” rating in a research note on Tuesday, March 4th. JMP Securities reaffirmed a “market outperform” rating and issued a $28.00 target price on shares of Kura Oncology in a research report on Thursday, February 6th. Finally, Scotiabank reduced their price target on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a research report on Wednesday, January 8th. Three analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Kura Oncology presently has a consensus rating of “Moderate Buy” and an average price target of $25.50.

Kura Oncology Trading Down 3.6 %

The company’s fifty day moving average is $7.81 and its two-hundred day moving average is $11.85. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The stock has a market cap of $514.01 million, a price-to-earnings ratio of -2.69 and a beta of 0.85.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.43. The firm had revenue of $53.88 million for the quarter, compared to analysts’ expectations of $57.96 million. On average, research analysts predict that Kura Oncology, Inc. will post -2.44 EPS for the current fiscal year.

Insider Activity

In other Kura Oncology news, insider Mollie Leoni sold 4,963 shares of the company’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the completion of the transaction, the insider now owns 88,253 shares in the company, valued at $694,551.11. This represents a 5.32 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Thomas James Doyle sold 4,949 shares of the firm’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the transaction, the senior vice president now directly owns 88,193 shares in the company, valued at approximately $694,078.91. The trade was a 5.31 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 11,729 shares of company stock worth $92,307. 5.50% of the stock is currently owned by insiders.

Institutional Trading of Kura Oncology

Large investors have recently made changes to their positions in the company. Virtus ETF Advisers LLC lifted its stake in Kura Oncology by 71.6% in the fourth quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company’s stock valued at $64,000 after buying an additional 3,061 shares during the last quarter. Point72 DIFC Ltd purchased a new stake in Kura Oncology in the 3rd quarter valued at $146,000. Harbor Advisors LLC acquired a new stake in Kura Oncology during the 4th quarter worth $87,000. E Fund Management Co. Ltd. purchased a new position in Kura Oncology during the 4th quarter worth $90,000. Finally, Erste Asset Management GmbH acquired a new position in Kura Oncology in the third quarter valued at $215,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.